

## Transforming Drug Development and Regulatory Assessments: Is it Possible?

Lilliam Rosario, PhD

Director, Office of Computational Science

Office of Translational Science, CDER, FDA





## **Disclaimer**

The views and opinions presented here represent those of the speakers and should not be considered to represent advice or guidance on behalf of the U.S. Food and Drug Administration.









FDA recognizes the need to improve efficiencies and encourages the use of standardized data









CDISC standards are developed

FDA encourages submission of SDTM and ADaM



And ....SEND

















- 2012 FDASIA, Title XI Section 1136
- 2014: Providing Regulatory Submissions in Electronic Format
- 2014: Providing Regulatory Submissions in Electronic Format: Standardized Study Data
- 2014: Study Data Technical Conformance Guide and Data Standards Catalog


  https://www.fda.gov/industry/fda.dat

















## Optimizing the Use of Data Standards

- Clinical Integrated Study Data and Analysis Data Reviewer's Guide
- Best Practices in Data Standards
   Implementation Governance
- SDTM ADaM FAQ Implementation
- Management of ODS Regulatory Referenced Deliverables
- Implementation of Estimands (ICH E9 (R1)) using Data Standards


## **Nonclinical Topics**

- SEND Implementation User Group
- SEND Industry Feedback Survey
- Conformance with the tumor.xpt Specification
- Harmonization of SEND Implementation to Enable Historical Control Data Analysis
- Nonclinical Protocol Automation
- Nonclinical Scripts
- Nonclinical Study Data Reviewers Guide

https://advance.phuse.global/display/WEL/Working+Groups



- Office of Computational Science offers services, training and Service Desk support
- Reviewers prepared to embrace electronic data



**Study Data Standards Resources** 














- New paradigm in regulatory review
- How do we use technology?
- How do we collaborate?





